PLoS Pathogens · 2011 · 149 citations · 29 references
Life SciencesMicrobiologyDrug DiscoveryGene ExpressionMicrobial MetabolismAmino Acid MetabolismBacterial Gene RegulationMetabolic Pathway EngineeringMicrobial Metabolic EngineeringMicrobial Synthetic BiologyBacterial Growth KineticsBiotin BiosynthesisMurine ModelsMycobacterium Tuberculosis InfectionMycobacterium Tuberculosis PathogenesisPost-transcriptional Gene SilencingTranscriptional Gene SilencingTuberculosis Drug Development
In the search for new drug targets, we evaluated the biotin synthetic pathway of Mycobacterium tuberculosis (Mtb) and constructed an Mtb mutant lacking the biotin biosynthetic enzyme 7,8-diaminopelargonic acid synthase, BioA. In biotin-free synthetic media, ΔbioA did not produce wild-type levels of biotinylated proteins, and therefore did not grow and lost viability. ΔbioA was also unable to establish infection in mice. Conditionally-regulated knockdown strains of Mtb similarly exhibited impaired bacterial growth and viability in vitro and in mice, irrespective of the timing of transcriptional silencing. Biochemical studies further showed that BioA activity has to be reduced by approximately 99% to prevent growth. These studies thus establish that de novo biotin synthesis is essential for Mtb to establish and maintain a chronic infection in a murine model of TB. Moreover, these studies provide an experimental strategy to systematically rank the in vivo value of potential drug targets in Mtb and other pathogens.
29
Stoyan Bardarov, Svetoslav Bardarov, Martin S. Pavelka et al. · Microbiology · 2002 · 599 citations
Christian Hoffmann, Andrew Leis, Michael Niederweis et al. · Proceedings of the National Academy of Sciences · 2008 · 598 citations · Full text